Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.70 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.70 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164261 | 0.92 | GABRA1 (0.63) | GABRA1GABRB2GABRB1GABRA3CYP1A2 | |
| SCHEMBL17242463 | 0.90 | GABRA1 (0.66) | GABRA1GABRB2GABRB1GABRA3CYP1A2 | |
| SCHEMBL29576698 | 0.90 | GABRA1 (0.60) | GABRA1GABRB2GABRB1GABRA3CYP1A2 | |
| SCHEMBL5681642 | 0.90 | GABRA1 (0.60) | GABRA1GABRB2GABRB1GABRA3CYP1A2 | |
| SCHEMBL18987742 | 0.90 | GABRA1 (0.60) | GABRA1GABRB2GABRB1GABRA3CYP1A2 | |
| SCHEMBL10519075 | 0.90 | GABRA1 (0.66) | GABRA1GABRB2GABRB1GABRA3CYP1A2 | |
| SCHEMBL2031515 | 0.89 | GABRA1 (0.59) | GABRA1GABRB2GABRB1GABRA3CYP1A2 | |
| SCHEMBL28289153 | 0.86 | GABRA1 (0.69) | GABRA1GABRB2GABRB1GABRA3CYP1A2 | |
| SCHEMBL10867175 | 0.85 | GABRA1 (0.58) | GABRA1GABRB2GABRB1GABRA3CYP1A2 | |
| SCHEMBL4840379 | 0.85 | GABRA1 (0.56) | GABRA1GABRB2GABRB1GABRA3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694851-B1 | ENVIRONMENTALLY DEGRADABLE QUINOLONE ANTIBIOTICS HAVING A HEMIAMINAL STRUCTURAL UNIT | LEUPHANA UNIV LUENEBURG STIFTUNG OEFFENTLICHEN RECHTS (DE) | 2023-12-27 | — | — | EP | disclosed |
| EP-3390384-B1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2021-09-15 | — | — | EP | disclosed |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3694851-A1 | ENVIRONMENTALLY DEGRADABLE QUINOLONE ANTIBIOTICS HAVING A HEMIAMINAL STRUCTURAL UNIT | Leuphana Universität Lüneburg Stiftung Öffentlichen Rechts (DE) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019072905-A1 | ENVIRONMENTALLY DEGRADABLE QUINOLONE ANTIBIOTICS HAVING A HEMIAMINAL STRUCTURAL UNIT | LEUPHANA UNIVERSITAET LUENEBURG STIFTUNG OEFFENTLICHEN RECHTS (DE) | 2019-04-18 | — | — | WO | disclosed |
| US-10150736-B2 | Haptens and immunoreactive agents and use thereof for producing family antibodies and immunoassays for quinolones | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2018-12-11 | — | — | US | disclosed |
| EP-3390384-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | Astex Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103851-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| US-20130273581-A1 | HAPTENS AND IMMUNOREACTIVE AGENTS AND USE THEREOF FOR PRODUCING FAMILY ANTIBODIES AND IMMUNOASSAYS FOR QUINOLONES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2013-10-17 | — | — | US | disclosed |
| US-7879878-B2 | such as {2-[({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]ethyl}phosphonic acid, used as platelet aggregation inhibitor and purinergic receptor (P2Y12) inhibitors; therapy for circulatory diseases involving thrombosis via platelet aggregation | ASTELLAS PHARMA INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-1083920-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064051-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0321191-B1 | Heterocyclic-substituted quinoline-carboxylic acids | PFIZER (US) | 1994-11-02 | — | — | EP | disclosed |
| US-5214051-A | Thiazolyl and oxazolyl[5,4-c]piperidyl-substituted quinolone-carboxylic acid and related analogs thereof having antibacterial properties are disclosed | PFIZER INC. (US) | 1993-05-25 | — | — | US | disclosed |
| US-5037834-A | Heterocycylic-substituted quinoline-carboxylic acids | PFIZER INC. (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0200307-B1 | IMPROVED PROCESS FOR PRODUCTION OF QUINOLINE-3-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1989-12-20 | — | — | EP | disclosed |
| WO-1989005643-A1 | HETEROCYCLIC-SUBSTITUTED QUINOLINE-CARBOXYLIC ACIDS | PFIZER INC. (US) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273581-A1 | HAPTENS AND IMMUNOREACTIVE AGENTS AND USE THEREOF FOR PRODUCING FAMILY ANTIBODIES AND IMMUNOASSAYS FOR QUINOLONES | NQO2, NISCH, VIP | GABRA1 2098/4885GABRB2 2831/4885GABRB1 2980/4885 |
| US-10150736-B2 | Haptens and immunoreactive agents and use thereof for producing family antibodies and immunoassays for quinolones | NQO2, NISCH, VIP | GABRA1 2098/4885GABRB2 2831/4885GABRB1 2980/4885 |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | HPGDS, PTGS1, PTGIS | GABRA1 3120/4885GABRB2 3784/4885GABRB1 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.